Anti-Bcma Car T Cell Compositions
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 12,109,234 | Anti-Bcma Car T Cell Compositions In force · High confidence | 2SEVENTY Bio, Inc. | In force | High confidence | ||
| Application 18/820,674 | Anti-Bcma Car T Cell Compositions Pending Not granted | 2SEVENTY Bio, Inc. | Pending | Not granted | ||
| Application 18/820,757 | Anti-Bcma Car T Cell Compositions Pending Not granted | 2SEVENTY Bio, Inc. | Pending | Not granted |
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by 2SEVENTY Bio, Inc..
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.